FOSUNPHARMA(SH:600196) 创业家·2026-01-02 09:59Group 1 - The core viewpoint of the article revolves around the controversial acquisition of Green Valley Pharmaceutical by Fosun Pharma, which has raised significant skepticism due to the financial health of Green Valley and the uncertain future of its key product, GV-971, also known as "Jiuyiqi" [6][10][12]. - Fosun Pharma announced a plan to acquire Green Valley for 1.412 billion yuan, despite Green Valley's net assets being only approximately 10.36 million yuan, leading to concerns about the high premium paid for a company in financial distress [10][16]. - Green Valley's main product, Jiuyiqi, has faced production halts due to the expiration of its registration certificate, resulting in a significant drop in revenue and a net loss of 6.7 million yuan in the first three quarters of the year [10][16][18]. Group 2 - The article discusses the historical context of Green Valley's founder, Lu Songtao, and the controversies surrounding the company's previous products, which have contributed to skepticism about Jiuyiqi's efficacy and the company's credibility [20][26][30]. - Fosun Pharma's response to regulatory inquiries emphasizes their confidence in Jiuyiqi's potential, outlining a phased payment structure for the acquisition that allows for risk mitigation based on the drug's clinical trial outcomes [18][19]. - The market potential for Jiuyiqi is highlighted, with estimates suggesting a target population of approximately 3.56 million and a projected peak sales value of around 4 billion yuan by 2035 if the drug is successfully reintroduced to the market [33][34].